| Dr R J Moen, MD | |
|
300 N 7th St, Bismarck, ND 58501-4439 | |
| (701) 323-6000 | |
| (701) 323-5918 |
| Full Name | Dr R J Moen |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 300 N 7th St, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528092772 | NPI | - | NPPES |
| 25718 | Other | ND | BLUE CROSS OF ND |
| 11585 | Medicaid | ND | |
| 0144636 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 8772 (North Dakota) | Secondary |
| 207Q00000X | Family Medicine | 8772 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Bismarck | Bismarck, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Bismarck | 9739098575 | 448 |
News Archive
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
The US Government's increased recommendations for increased daily calcium intake, largely from dairy products, to between 800 and 1,300 milligrams to promote healthy bones and prevent osteoporosis is being queried.
UK-based biotechnology firm ILC Therapeutics is working alongside the University of Oxford to examine the use of Evasins – molecules derived from ticks – as a potential COVID-19 treatment option for patients whose lungs are badly damaged by the virus and face a critical juncture in recovery.
Medical records are an invaluable tool in treating patients. When a caregiver has ample information regarding a person's medical history, treatments are more effective and efficient. Unfortunately, few people have complete medical records - due, in large part, to a lack of any universal repository tools for keeping those records.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 1 days ago
| Entity Name | Sanford Bismarck |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811941172 PECOS PAC ID: 9739098575 Enrollment ID: O20031105000403 |
News Archive
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
The US Government's increased recommendations for increased daily calcium intake, largely from dairy products, to between 800 and 1,300 milligrams to promote healthy bones and prevent osteoporosis is being queried.
UK-based biotechnology firm ILC Therapeutics is working alongside the University of Oxford to examine the use of Evasins – molecules derived from ticks – as a potential COVID-19 treatment option for patients whose lungs are badly damaged by the virus and face a critical juncture in recovery.
Medical records are an invaluable tool in treating patients. When a caregiver has ample information regarding a person's medical history, treatments are more effective and efficient. Unfortunately, few people have complete medical records - due, in large part, to a lack of any universal repository tools for keeping those records.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr R J Moen, MD Po Box 5074, Sioux Falls, SD 57117-5074 Ph: (605) 328-6585 | Dr R J Moen, MD 300 N 7th St, Bismarck, ND 58501-4439 Ph: (701) 323-6000 |
News Archive
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
The US Government's increased recommendations for increased daily calcium intake, largely from dairy products, to between 800 and 1,300 milligrams to promote healthy bones and prevent osteoporosis is being queried.
UK-based biotechnology firm ILC Therapeutics is working alongside the University of Oxford to examine the use of Evasins – molecules derived from ticks – as a potential COVID-19 treatment option for patients whose lungs are badly damaged by the virus and face a critical juncture in recovery.
Medical records are an invaluable tool in treating patients. When a caregiver has ample information regarding a person's medical history, treatments are more effective and efficient. Unfortunately, few people have complete medical records - due, in large part, to a lack of any universal repository tools for keeping those records.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 1 days ago
Gary Robert Betting, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 515 E Broadway, Center For Family Medicine, Bismarck, ND 58501 Phone: 701-751-9500 Fax: 701-751-9508 | |
James B Bossort, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 Fax: 701-323-5709 | |
Haily Datz, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 701 E Rosser Ave, Bismarck, ND 58501 Phone: 701-751-9500 Fax: 701-751-9508 | |
Monika Pothamsetti, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 701 E Rosser Ave, Bismarck, ND 58501 Phone: 701-751-9500 | |
Olimpia Rauta, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 Fax: 701-323-8305 | |
Dr. Jeremiah Jon Penn, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 N 9th St., Bismarck, ND 58501 Phone: 701-530-6000 Fax: 701-530-6422 | |
Dr. Todd W Schaffer, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 3318 N 14th St, Bismarck, ND 58503 Phone: 701-323-8300 Fax: 701-323-8305 |